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Abstract
Unbalanced (major route) additional cytogenetic aberrations (ACA) at diagnosis of chronic
myeloid leukemia (CML) indicate an increased risk of progression and shorter survival.
Moreover, newly arising ACA under imatinib treatment and clonal evolution are considered
features of acceleration and define failure of therapy according to the European Leukemia-
Net (ELN) recommendations. On the basis of 1151 Philadelphia chromosome positive
chronic phase patients of the randomized CML-study IV, we examined the incidence of
newly arising ACA under imatinib treatment with regard to the p210BCR-ABL breakpoint
variants b2a2 and b3a2. We found a preferential acquisition of unbalanced ACA in patients
with b3a2 vs. b2a2 fusion type (ratio: 6.3 vs. 1.6, p = 0.0246) concurring with a faster prog-
ress to blast crisis for b3a2 patients (p = 0.0124). ESPL1/Separase, a cysteine endopepti-
dase, is a key player in chromosomal segregation during mitosis. Separase overexpression
and/or hyperactivity has been reported from a wide range of cancers and cause defective
mitotic spindles, chromosome missegregation and aneuploidy. We investigated the influ-
ence of p210BCR-ABL breakpoint variants and imatinib treatment on expression and pro-
teolytic activity of Separase as measured with a specific fluorogenic assay on CML cell
lines (b2a2: KCL-22, BV-173; b3a2: K562, LAMA-84). Despite a drop in Separase protein
levels an up to 5.4-fold increase of Separase activity under imatinib treatment was observed
exclusively in b3a2 but not in b2a2 cell lines. Mimicking the influence of imatinib on BV-173
and LAMA-84 cells by ESPL1 silencing stimulated Separase proteolytic activity in both
b3a2 and b2a2 cell lines. Our data suggest the existence of a fusion type-related feedback
mechanism that posttranslationally stimulates Separase proteolytic activity after therapy-in-
duced decreases in Separase protein levels. This could render b3a2 CML cells more prone
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to aneuploidy and clonal evolution than b2a2 progenitors and may therefore explain the cy-
togenetic results of CML patients.
Introduction
The BCR-ABL tyrosine kinase (TK) formed by the balanced translocation t(9;22)(q34;q11) is
the “key player” in the pathogenesis of chronic myeloid leukemia (CML). Its deregulated TK
activity affects various downstream signaling pathways and results in reprogramming of the
prior lineage commitment of hematopoietic stem and early progenitor cells. [1] Compromising
multiple aspects of the affected hematopoietic stem cell, including proliferation, apoptosis, cell
to cell signaling and differentiation, the BCR-ABL oncoprotein triggers aberrant clonal hema-
topoiesis and drives disease progression from chronic phase (CP) toward the fully transformed
phenotype of blast crisis (BC). [2]
Imatinib (IM) is a selective TK inhibitor (TKI) and represents one of the current first line
treatment options for CML. [3] However, persistence of so-called leukemia stem cells (LSCs)
with low BCR-ABL expression, insensitivity to IM treatment and long term survival capacity
has been observed. [4] Acquisition of additional genetic lesions in LSCs or their progeny drives
leukemic transformation from CML CP to accelerated phase (AP) or BC. [5]
Genomic instability and aneuploidy are hallmarks of the progressing CML and concur with
BCR-ABL mutations encoding resistance to TKI and/or development of additional chromo-
somal aberrations (ACA) in addition to the Philadelphia chromosome (Ph) (= clonal evolu-
tion). [6,7] About 35% of patients in CP develop resistance or intolerance to IM and frequently
undergo clonal evolution. [8,9] While approximately 10–12% of patients in CML CP display
ACA at diagnosis, this proportion of patients rises to approximately 30% and 80% in AP and
BC, respectively. [10,11] Recently, we have shown that major route ACA (all unbalanced, e.g.
second Ph, trisomy 8, isochromosome 17q, or trisomy 19) at diagnosis are associated with a
negative impact on survival and signify progression to AP and BC. [12] Moreover, clonal evo-
lution during the course of CML is considered a feature of acceleration and indicate poor prog-
nosis as patients with ACA show lower cytogenetic response rates under IM. [6,13,14]
According to the European LeukemiaNet (ELN) recommendations newly arising ACA under
IM treatment define failure of therapy. [3,15]
The occurrence of supernumerary centrosomes (= centrosome amplification) is the major
cause of multipolar mitotic spindle formation and chromosomal missegregation leading to
chromosomal instability (CIN) and aneuploidy. [16–18] Centrosome amplification, in particu-
lar, the accumulation of additional centrosomes (n>2), is frequently detected in solid and he-
matological human cancers and has already been found in pre-neoplastic lesions i.e. early
stages of carcinogenesis. [19,20] CIN is considered to continually drive clonal evolution and
tumor heterogeneity. [21,22]
In CML, centrosome amplification is an early event in the transformation process and oc-
curs at the earliest identifiable step in CML development. [17] Recently, in a long-term in vitro
study on a CML CP model we have established the functional link of p210BCR-ABL TK activi-
ty with centrosome amplification and clonal evolution. [23] This is in accordance with the ob-
servation that p210BCR-ABL and c-ABL are both centrosome associated proteins. [24]
However, IM treatment did not prevent the development of centrosome amplification; but by
itself induced centrosomal and/or cytogenetic alterations in several bcr-abl-negative cell line
models and in vivo. [25–29]
Separase Activity in CML
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The maintenance of regular centrosome numbers in non-malignant cells depends on the or-
dered centriole duplication strictly limited to once per cell cycle. Disengagement of mother and
daughter centriole is a prerequisite for semiconservative centriole duplication and is provided
by proteolytic cleavage of cohesin, a “glue”multi-protein complex that is also responsible for
sister-chromatide cohesion. [30–32] Separase, a cysteine endopeptidase encoded by the gene
espl1, conducts cleavage of cohesin. [32–34] Ectopic activation of Separase proteolytic activity
causes premature sister-chromatide separation and centriole disengagement and overexpres-
sion of Separase has been reported to induce centrosome amplification, aneuploidy and tumor-
igenesis. [31,35] Recently, striking functional evidence for the oncogenic activity of deregulated
Separase was provided by Pati and coworkers who have generated a transgenicMMTV-Espl1
mouse model that overexpresses Separase protein in the mammary gland. These mice devel-
oped aggressive and highly aneuploid mammary carcinomas with high levels of CIN and cell
cycle defects including multiple centrosomes and multinucleated cells. [36] Moreover, Separase
overexpression has been considered as potential predictor of progression-free survival and re-
lapse in glioblastoma. [37]
The proteolytic activity of Separase is tightly regulated by multiple inhibitory mechanisms
combining Securin binding, specific serine residue phosphorylation (pSer1126) by CyclinB1/
Cdk1, autocatalytic cleavage and PP2A-dependent stabilization of Separase-bound Securin.
[38–41] The finding that espl1/Separase acts as an oncogene/-protein in various cancers includ-
ing CML renders this protease a key target to unravel the molecular mechanisms involved in
the development of centrosome amplification and clonal evolution in IM-treated CML.
[24,27,35,42]
In this study, we used the cytogenetic data from CML study IV to investigate incidences of
newly arising unbalanced ACA and blast crises under IM long-term treatment with regard to
the p210BCR-ABL breakpoint variants b2a2 and b3a2. In search for potential underlying mo-
lecular mechanisms we performed protein biochemical studies on Separase expression and ac-
tivity profiles in a panel of b2a2 and b3a2 CML cell lines. Our data point to the existence of a
p210BCR-ABL-dependent feedback mechanism that posttranslationally stimulates Separase
proteolytic activity after an IM-induced decrease in Separase protein levels exclusively in b3a2
cells. As a known promoter of aneuploidy and clonal evolution hyperactive Separase is an ex-
cellent candidate for explaining the cytogenetic in vivo data.
Materials and Methods
Cell lines and culture conditions
Six human cell lines were investigated. NHDF was derived from Promocell GmbH (Heidelberg,
Germany). KCL-22, BV-173, LAMA-84 and K562 were obtained from the DSMZ (German
Collection of Microorganisms and Cell Cultures, Braunschweig, Germany). The immortalized
human urothelial cell line UROtsa was a gift of the Department of Urology, Mannheim Medi-
cal Center, Mannheim Germany and cultured as previously described. [43] All cells were cul-
tured in RPMI-1640 supplemented with 10% fetal bovine serum, 2% glutamine and 1%
penicillin-streptomycin (Gibco/Invitrogen, Karlsruhe, Germany) at 37°C in 5% CO2 atmo-
sphere. Exponentially growing cells were used in at least triplicate experiments.
Patients and ethics statement
Clinical and cytogenetic data of 1151 patients with Ph+ and BCR-ABL+ CP CML randomized
to the German CML-Study IV (imatinib 400 mg vs. imatinib 800 mg vs. imatinib in combina-
tion with IFN vs. imatinib in combination with low-dose cytarabine vs. imatinib after IFN fail-
ure) were investigated. [12] Mean observation time was 5.6 years. There were 459 female (40%)
Separase Activity in CML
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and 692 male (60%) patients with a median age of 53 years (range, 16–88); median age was
lower in ACA patients (48 years). The definitions of CML phases followed the ELN recommen-
dations. [3] The protocol followed the declaration of Helsinki and was approved by the IRB/
Medizinische Ethikkommision II der Medizinischen Fakultät Mannheim der Ruprecht-Karls-
Universität Heidelberg. (http://www.umm.uni-heidelberg.de/inst/ethikkommission, # 0214.6
from 2002-08-21). Written informed consent was obtained from all patients before they en-
tered the study. The CML study IV is registered at www.clinicaltrials.gov as # NCT00055874.
Imatinib treatment
Cells were treated with IM (Biomol GmbH, Hamburg, Germany) in concentrations of 1 to
10μM for 24h (KCL-22, LAMA-84, K562), 48h (BV-173) and 6d (NHDF, UROtsa). Untreated
cells served as controls.
Separase silencing by espl1-directed siRNA
Espl1-specific siRNA (FlexiTube GeneSolution GS9700 for espl1) was purchased from Qiagen,
(Hilden, Germany). As negative controls the same cells were transfected with AllStars Negative
Control siRNA (Qiagen) a nonsilencing siRNA with no homology to any known mammalian
gene. Transfection was accomplished using the Nucleofector manual (program T016, Lonza
GmbH, Cologne, Germany). For siRNA treatment, 5x106 BV-173 cells and 2x106 LAMA-84
cells were resuspended in 100 μl Cell Line Nucleofector Solution V (LAMA-84) or Solution R
(BV-173) (Lonza) containing 18 μl Supplement S Solution (Lonza). SiRNA was added to a final
concentration of 0.01 nmol per 106 cells.
Quantification of espl1 transcripts by qRT-PCR
Total RNA was extracted using RNeasy kit (Qiagen) and reverse transcribed using Superscript
II kit (Gibco/Invitrogen). For quantification of separase (espl1) transcript levels, the commer-
cial Hs_ESPL1_1_SG QuantiTect Primer Assay (Qiagen) was employed according to the in-
structions (two-step LightCycler 480 protocol) of the manufacturer. For normalization, the
housekeeping gene beta-glucuronidase (gus, NM_000181, GUSB, primer set Hs_GUSB_1_SG,
QuantiTect Primer Assay, Qiagen) was amplified. QRT-PCR was performed with the Roche
LightCycler 480 System, using LC480 DNAMaster SYBR Green and the standard LightCycler
protocol (Roche Diagnostics, Mannheim, Germany). Relative transcript levels calculated from
triplicate measurements were calculated by the 2-ΔΔCT method with values normalized to gus
and relative to transcription in untreated control cells. [44]
Western blot analysis, antibodies
Western blot immunostaining of p210BCR-ABL, pCrkL, Separase, Securin, CyclinB1 and
Actin was performed as described previously. [42]
Karyotype analysis
Cytogenetic analysis was performed as described previously. [26] At least 20 metaphases were
analyzed by G- or R-banding technique and interpreted according to the International System
for Human Cytogenetic Nomenclature (ISCN 2009).
Separase Activity in CML
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Separase activity assay
About 60 μg cleared native protein lysate was analyzed in a quantitative fluorogenic assay ac-
cording to Basu and coworkers. [45] Spectrofluorometry was performed as described previous-
ly. [42]
Statistical analysis
All statistical calculations have been done with GraphPad Prism software version 5.0 (Graph-
Pad Inc., La Jolla, USA) or SAS software, release 9.3 (SAS Institute Inc.,Cary, NC, USA). Quan-
titative parameters are presented as mean values together with standard deviation (SD) or 95%
confidence intervals (CI). For qualitative data, absolute and relative frequencies are given. In
order to compare two mean values, two-tailed unpaired t tests have been used. Frequencies
have been compared using Chi2 or Mann-Whitney-U-tests. All tests have been performed
2-sided. Test results with p<0.05 were considered significant. Values between p0.05 and
p0.1 were defined as trend.
Results
Long-term survey of IM-treated CML patients confirms preferential
acquisition of unbalanced ACA in patients with the b3a2 fusion type of
p210BCR-ABL
To investigate the conditional context between bcr-abl breakpoint variant (b3a2 or b2a2), IM
therapy and acquisition of ACA and clonal evolution we have analyzed therapy-related acquisi-
tion of ACA in 1151 patients under IM treatment that were randomized to the CML-Study IV.
[12] To test for diverse ACA acquisition rates in b2a2 vs. b3a2 CML patients, all patients
(n = 1151) were classified according to their bcr-abl breakpoint variant and the appearance of
ACA during the course of the disease that were not detectable at diagnosis (before IM treat-
ment). As given in Table 1, a total of 978 patients (463 with b2a2 and 515 with the b3a2 vari-
ant) were selected from this study. 173 of 1151 patients (15%) were omitted because they
carried both or switched (n = 7) between b2a2 and b3a2 bcr-abl breakpoint variants within the
observation period. Of the remaining patients (n = 978) ACA acquisitions during IM therapy
were discovered in 36 (7.8%) and 29 (5.6%) patients with the b2a2 and b3a2
variant, respectively.
Since chromosomal missegregations are the first line consequences of defective mitotic spin-
dles concurring with supernumerous centrosomes (associated with overactive Separase), the
observed ACA were further classified with respect to the types “balanced” (no change in DNA
content, e.g. reciprocal translocation) or “unbalanced” (chromosomal losses and gains)
(Table 2). The latter serves best as a direct measure of mitotic spindle failure as no additional
DNAmodifying enzymes (e.g. DNA polymerases of DNA repair) are involved. While in the
Table 1. Occurrence of ACA in CML patients (n = 978) of the randomized CML Study IV during long
term treatment with IM.
Numbers and patient characteristics b2a2 (e13a2) b3a2 (e14a2)
t(9 ;22)(q34 ;q11), - ACA 427 (92.2%) 486 (94.4%)
t(9 ;22)(q34 ;q11), + ACA 36 (7.8%) 29 (5.6%), p = 0.1789
463 (100%) 515 (100%)
ACA, additional clonal cytogenetic alteration
doi:10.1371/journal.pone.0129648.t001
Separase Activity in CML
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b2a2 group the proportion of type “unbalanced” to “balanced” was 22:14 (61%:39%, ratio 1.6),
a ratio of 25:4 (86%:14%, ratio 6.3) was found in the b3a2 patient group (p = 0.0246). The pref-
erential occurrence of unbalanced ACA in the Ph+ clone (for karyotypes see S1 Table) of IM
treated patients with the b3a2 fusion type coincides with a faster progress to blast crisis for
b3a2 patients (p = 0.0124, median and range in months: 9 (3–15) vs. 25 (6–48). This suggests
the existence of a molecular mechanism that favours disease progress via chromosomal misse-
gregation, aneuploidy and clonal evolution specifically in p210BCR-ABL progenitors with the
b3a2a fusion type. No further differences between b3a2 and b2a2 patient groups regarding dis-
tinct abnormalities in hematologic features or in time under IM until detection of ACA (b2a2:
23 (2–87); b3a2: 21 (1–101) were found.
Experimental design and cell line characterization
In search for potential underlying molecular mechanisms we performed comparative studies
on Separase expression and activity profiles in a panel of b2a2 and b3a2 CML cell lines. The ex-
periments aimed at confirming and expanding previously published work. [42] Here, analo-
gous cell culture experiments were performed on six human cell lines (Table 3) with focus on
the comparison between b2a2 (KCL-22, myeloblastic; BV-173, lymphoblastic) and b3a2 cell
lines (LAMA-84, myeloblastic; K562, lymphoblastic). Primary NHDF cells and SV-40 immor-
talized UROtsa served as models for non-malignant cells. Analyzing the changes that occur
within the first few rounds of the cell cycle after IM administration, our experimental setting
should provide insight into Separase post-translational regulatory mechanisms occuring im-
mediately after IM administration before any phenotypic alterations in centrosomal or cyto-
genetic status may manifest. Since the proteolytic activity of Separase in non-malignant cells is
tightly restricted to the mitotic anaphase and is therefore regulated in a cell cycle-dependent
manner, treatment periods were chosen with respect to the respective cell doubling times so
that at least one cell cycle round was completed under IM treatment and less than 12% of cells
were apoptotic. We considered cell doubling times as the best approximative estimation of cell
cycle transits albeit we are aware that these values do not reflect potential loss of cells by cell
death and delayed exit of cells from the cell cycle. However, we assigned 6d (NHDF, UROtsa),
48h (BV-173) and 24h (KCL-22, LAMA-84, K562) of treatment as appropriate before cell har-
vesting and target analysis (Table 3). All cell lines were treated with therapeutic doses of IM
(range: 1 to 10 μM) as performed in our previous studies. [23,26,27,42] In accordance with
data from extensive studies on the dose-dependent effects and time kinetics of IM we applied
lower IM doses (range: 1 μM to 2.5 μM) for leukemia-derived p210BCR-ABL-positive cells
(KCL-22, BV-173, K562 and LAMA-84) than for p210BCR-ABL-negative cells (range: 2.5 μM
Table 2. Classification of ACA arisen during long term treatment with IM.
Numbers and patient characteristics b2a2 (e13a2): n = 36 b3a2 (e14a2): n = 29
t(9;22)(q34 ;q11) + ACA unbalanced 22 (61%) 25 (86%)
t(9 ;22)(q34 ;q11) + ACA balanced 14 (39%) 4 (14%)
Ratio (ACA unbalanced/balanced) * 1.6 6.3, p = 0.0246
Blast crises within observation period * 8 (22%) 7 (24%), p = 0.8554
Time to unbalanced ACA, median and range [months] # 23 (2–87) 21 (1–101), p = 0.9150
Time to BC, median and range [months] # 25 (6–48) 9 (3–15), p = 0.0124
ACA, additional clonal cytogenetic alteration
* Chi2-test
# Mann-Whitney-U-test
doi:10.1371/journal.pone.0129648.t002
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to 10 μM). [46–48] Treating CML cell lines with IM doses higher than 2.5 μM for a longer peri-
od than 48h impeded the collection of enough viable cells for Western blot analysis and Separ-
ase activity assays (data not shown).
All untreated cell lines were tested thoroughly with respect to bcr-abl expression, karyotype
and centrosome status, and proliferation rate. The protein levels of p210BCR-ABL, phosphory-
lation of CrkL at Tyr207 (pCrkL) as surrogate marker of ABL- and p210BCR-ABL-related ki-
nase activity and of Separase were analyzed (Fig 1). As expected, p210BCR-ABL protein was
detected exclusively in bcr-abl-positive cell lines (Fig 1A). The b2a2 variant cell lines KCL-22
and BV-173 displayed higher levels of p210BCR-ABL protein (163.1% and 168.2 +/- 77.6
(SD)%, respectively) than the b3a2 CML cell lines LAMA-84 and K562 (128 +/- 61.3(SD)%
and 100.0 +/- 18.7(SD)%, respectively). Densitometric analysis of pCrkL (Fig 1B) revealed the
highest phosphorylation levels in K562 (= 100% phosphorylation), followed by KCL-22
(68.6%), LAMA-84 (48.2 +/- 20(SD)%) and BV-173 (27.8 +/- 7.6(SD)%) pointing to the consti-
tutive TK activity of p210BCR-ABL. Minor phosphorylation levels for pCrkL were detected in
NHDF (2.1 +/- 1.9(SD)%) and UROtsa cells (1.4 +/- 1.3(SD)%).
Table 3. Origin and characteristics of human cell line models under investigation.
Cell
line
Cell type Origin Doubling
time [h] 1
BCR-ABL-
copy no/
type
centrosomal
status [%] 2
Cytogenetics Used as
model
for
NHDF normal human
dermal
ﬁbroblasts,
primary
juvenile foreskin,
from healthy donor
~ 72 none normal, < 5% 46,XY normal
cells
UROtsa human urothelial normal urothelial
cells immortalized
with SV40
~ 63 none normal, < 3% 46,XX normal
cells
KCL-22 human CML
(BC)
pleural effusion of
patient with CML
BC, myeloblastic
~24 2 / (b2a2) aberrant, 78% human hyperdiploid karyotype with
3.3% polyploidy– 51(47–51)<2n>X,-X,
+1, +6, +8, +8, +14, +22, del(1)(p22), t
(9;22)(q34;q11), add(17)(p12-13), i
(21q), der(22)t(9;22)(q34;q11)–carries
Phx2 –matches published karyotype
(DSMZ)
CML,
b2a2
BV-173 human CML
(BC)
PB of a patient with
CML BC,
lymphoblastic
~48 1 / (b2a2) aberrant, 10% human hyperdiploid karyotype– 47
(46–48)<2n>X/XY, -9, +22, +mar, add
(1)(q42), add(8)(p23), t(9;22)(q34;
q11), der(22)t(9;22)(q34;q11), der(?)t
(9;?)(?p11;?) (DSMZ)
CML,
b2a2
LAMA-
84
human CML
(BC)
PB of a patient with
CML BC,
myeloblastic
~ 50 4 / (b3a2) aberrant, 43% 73/74(69–77)<3n>XX,-X,+1,-2,+5,+6,
+8,+13,-14,+17,+17,-18,+22,+mar,del
(7)(p15),der(9)t(9 ;22)(q34 ;q11)x2,i
(11q), add (13)(q33),del(17)(p12),der
(22)t(9 ;22)(q34 ;q11)x4 (DSMZ)
CML,
b3a2
K562 human CML
(BC)
pleural effusion of a
patient with CML
BC, lymphoblastic
~ 36 11 / (b3a2) aberrant, 34% 61–68<3n>XX,-X,-3,+7,-13,-18,
+3mar,del(9)(p11/13), der(14)t(14;?)
(p11;?),der(17)t(17;?)(p11/13;?),der(?
18) t(15;?18)(q21;?q12),del(X)(p22)
(DSMZ)
CML,
b3a2
Abbreviations: PB, peripheral blood; CML, chronic myeloid leukemia; CP, chronic phase; BC, blast crisis; no, number; DSMZ, German Collection of
Microorganisms and Cell Cultures, Braunschweig, Germany
1 doubling time of subconﬂuent cells
2 Analysis of 100 cells by immunoﬂuorescence microscopy after centrosome (pericentrin) staining
doi:10.1371/journal.pone.0129648.t003
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Separase protein level analysis revealed a general overexpression (range 16 to 50-fold) in all
BCR-ABL-positive cells when compared to NHDF cells (Fig 1C). This is in line with various re-
ports on separase overexpression in cancers, including CML. [24,35] Moreover, Separase pro-
tein levels correspond to observed doubling times and p210BCR-ABL TK activity, as the fast-
growing leukemic cells (KCL-22, BV-173, LAMA-84 and K562) displayed higher Separase
protein levels (relative protein levels of 59 +/- 11(SD)%, 33 +/- 15(SD)%, 83 +/- 5.3(SD)% and
100 +/- 20(SD)%, respectively) than bcr-abl-negative slow-growing cells (NHDF 72h doubling
time, relative protein level 2.0 +/- 3.0(SD)%; UROtsa 63h doubling time, relative protein level
5.3 +/- 0.3(SD)%. Peak pattern comparison of graph B and graph C (Fig 1) suggests that Separ-
ase expression correlates positively with p210BCR-ABL TK activity confirming our recent re-
sults on U937p210BCR-ABL/c6 cells with inducible p210BCR-ABL expression (Tet-On). [42]
Separase protein levels decrease and Separase proteolytic activity
increases exclusively in b3a2 p210BCR-ABL-positive cell lines under IM
treatment
For non-malignant cells (NHDF, UROtsa) a tendency to dose-dependent decrease in Separase
protein levels were observed in Western blot immunostaining experiments after IM exposure
(Fig 2, Table 4). Protein levels dropped (range 30 to 34%) at IM concentrations of 5 μM. Separ-
ase proteolytic activity seems tightly linked to protein levels as dose-dependent decreases in
proteolytic activity were found in the IM-treated cell lines (Fig 2A). Relative Separase activity
losses of 1.2 (CI95%: -9.8 to 7.4) and 34% (CI95%: -65 to -3.1) were observed in NHDF and
UROtsa cells at concentrations of 5 μM IM, respectively (Table 4). Separase activity downregu-
lation concurs with increases in Securin and CyclinB1 protein levels, both posttranslational in-
hibitors of Separase.
Analogous experiments were performed with the p210BCR-ABL-positive cell lines KCL-22,
BV-173 (b2a2, Fig 2B), LAMA-84 and K562 (b3a2, Fig 2C). While in the p210BCR-ABL b2a2
cell lines KCL-22 and BV-173 no significant changes in Separase protein levels and proteolytic
activity were detected, the CML cell lines LAMA-84 and K562 displayed sensitivity to IM after
24h. Considerable decreases in Separase protein levels were achieved for LAMA-84 and K562
Fig 1. Protein and activity levels of p210BCR-ABL and Separase expression in cell lines under investigation. Protein levels of p210BCR-ABL (A),
pCrkL (B) and Separase (C) based on densitometric evaluation of immunostainedWestern blots were normalized to Actin as loading control. Abl-related TK
activity (BCR-ABL + c-ABL) was measured as pCrkL/Actin (B). Analyses were performed on protein lysates derived from p210BCR-ABL-positive (KCL-22,
BV-173, LAMA-84, K562) and-negative non-malignant cells (NHDF, UROtsa). KCL-22 and BV-173 carry the bcr-abl breakpoint variant b2a2, whereas
LAMA-84 and K562 display the b3a2 fusion gene variant. All values refer to that of K562 (= 100%).
doi:10.1371/journal.pone.0129648.g001
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Fig 2. Separase proteolytic activity and levels of master Separase proteolytic activity regulators in
bcr-abl-negative (A) and–positive cell lines (B, C) treated with IM. Cells were treated with IM for times
and doses [μM] given on top. Separase proteolytic activity was quantified using an in vitro fluorometric assay
and was given as relative fluorescence units/Actin (RFU/Actin). Analyses were performed on protein lysates
derived from bcr-abl-negative (A) control cells (NHDF, UROtsa) and from p210BCR-ABL-positive cells with
the bcr-abl breakpoint variant b2a2 (B) (KCL-22, BV-173) and variant b3a2 (C) (LAMA-84, K562). Each data
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PLOSONE | DOI:10.1371/journal.pone.0129648 June 18, 2015 9 / 18
with low doses (1 μM) of IM (Fig 2C) pointing to the strong proliferative p210BCR-ABL-de-
pendency of these cell lines as discussed by others. [46] Separase activation is an essential step
for completing mitosis and entering the next cell cycle round. Here, relative Separase protein
decreased by 75.8% (CI95%: -119.1 to -32.5) and 56.9 (CI95%: -77.4 to -36.5)% in LAMA-84
and K562 cells at concentrations of 2.5 and 1 μM IM, respectively (Table 4). Despite the ob-
served decrease in Separase protein levels, increased levels of Separase proteolytic activity were
measured (Fig 2C). Increases of 31.1% (CI95%: -0.04 to 62.2) and 9.1% (CI95%: 2.3 to 16.0)
were observed for LAMA-84 and K562 cells, respectively (Table 4). Confirming a previous data
set this concurs with conspicuous loss in the corresponding inhibitory protein levels of Securin
and CyclinB1. [42] To exemplify, Securin protein levels dropped by 82.1% (CI95%: -96.3 to
-68.0) and 44.3 (CI95%: 9.5 to 98.2) in LAMA-84 and K562 cells, respectively. As a result,
about 25% of the residual Separase protein perform about 130% proteolytic activity in LAMA-
84 cells (as calculated from Table 4) meaning an approximate 5.4-fold increase in Separase ac-
tivity when compared to the respective untreated cells. The same holds true for K562 cells
where a 2.5-fold activity increase in protease activity was estimated. Thus, the inhibitory effect
of IM on Separase protein expression seems to be counterbalanced by the increase in Separase
proteolytic activity. In fact, this proposed compensatory mechanism leads to a 31% increase in
overall Separase proteolytic activity (Table 4) in LAMA-84 and 9% increase in K562 cells when
compared to untreated cells. One might argue that the observed effect may be due to IM-
point corresponds to one single experiment. The protein levels of Separase, Securin, and CyclinB1 based on
densitometric evaluation of immunostained Western blots were normalized to Actin as loading control. The
correspondingWestern blot images are cropped sections derived from stripped and reprobedWestern blot
immunostainings used for acquisition of densitometric data shown in Table 4. At least triplicate Western blot
experiments were performed, one representative composite is depicted. Only significant p-values as
calculated between treated and untreated cells were shown (see Table 4 for summarized Δ-values).
Abbreviations: RFU, relative fluorescence units; IM, imatinib.
doi:10.1371/journal.pone.0129648.g002
Table 4. Percent changes (Δ-values are differences betweenmeans) in protein levels and proteolytic activity of Separase after IM treatment when
compared to corresponding untreated cells.
Cell line, period of
treatment
Separase protein
levels [%] 1,2
Securin protein
levels [%] 1,2
CyclinB1 protein
levels [%] 1,2
Separase proteolytic
activity [%]
Separase proteolytic
activity [fold change] 3
NHDF, 5 μM IM, 6d -34.4 (-54.0 to -14.9),
p = 0.0032
+67.7 (-24.9 to
160.3), p = 0.1302
+59.4 (-88.8 to 207.6),
p = 0.2920
-1.2 (-9.8 to 7.4),
p = 0.7817
1.5 (1.2 to 2.0)
UROtsa, 5 μM IM,
6d
-30.0 (-83.8 to 23.9),
p = 0.2124
+27.3 (-26.2 to 80.9),
p = 0.2583
+36.4 (-177.2 to
250.0), p = 0.5399
-34.2 (-65.2 to -3.1),
p = 0.0328
0.9 (0.6 to 2.1)
KCL-22, 2.5 μM IM,
24h
-11.8 (-98.7 to 75.1),
p = 0.7249
-45.6 (-98.0 to 6.7),
p = 0.0769
-44.6 (-69.6 to -19.7),
p = 0.0047
+7.4 (-2.1 to 16.9),
p = 0.1248
1.2 (0.7 to 4.4)
BV-173, 2.5 μM IM,
48h
-6.5 (-25.0 to 12.0),
p = 0.4797
+9.7 (-32.4 to 51.7),
p = 0.6101
+7.1 (-19.9 to 34.1),
p = 0.5931
+2.5 (-24.4 to 29.5),
p = 0.8457
1.1 (1.0 to 1.2)
LAMA-84, 2.5 μM
IM, 24h
-75.8 (-119.1 to
-32.5), p = 0.0064
-82.1 (-96.3 to -68.0),
p<0.0001
-34.2 (-71.7 to 3.4),
p = 0.0676
+31.1 (-0.04 to 62.2),
p = 0.0502
5.4 (**)
K562, 1 μM IM, 24h -56.9 (-77.4 to -36.5),
p = 0.0015
-44.3 (9.5 to 98.2),
p = 0.0844
-9.7 (-72.0 to 52.6),
p = 0.7166
+9.1 (2.3 to 16.0),
p = 0.0121
2.5 (1.9 to 3.7)
1 Δ-values were calculated from signiﬁcant data sets diagrammed in Fig 1. All values are normalized to Actin.
2 for representative corresponding immunostained Western blots see Fig 1.
3 calculated quotient of Separase proteolytic activity [%] / Separase protein level [%]. Example (K526): (100+9.1)/(100–56.9) = 2.5
Abbreviations: d, days; h, hours; IM, imatinib; +, increase;-, decrease.
The conﬁdence interval (95%CI) is given in parentheses.
** Since the CI of the denominator includes zero, it is not possible to compute the CI of this quotient.
doi:10.1371/journal.pone.0129648.t004
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related changes in the cell cycle, i.e. increased proportion of cells entering anaphase. However,
FACS analysis of tested cells revealed no breakpoint-specific differences neither in G2/M cell
proportion nor in the apoptotic cell fraction (<12%) that could clarify the observed phenome-
non of IM-induced Separase activation (data not shown). Further potential caveats related to
myeloblastic/lymphoblastic features of the analyzed CML cell lines (KCL-22: b2a2 and myelo-
blastic; BV-173: b2a2 and lymphoblastic; LAMA-84: b3a2 and myeloblastic; K562: b3a2 and
lymphoblastic) could be ruled out since the observed IM-related changes in Separase proteolyt-
ic activity correlate only with the splice variant but not with their morphological features.
Downregulation of Espl1/Separase by RNAi stimulates Separase
proteolytic activity in b3a2 and b2a2 p210BCR-ABL-positive cells
To test for the existence of a regulatory mechanism that may control Separase proteolytic activ-
ity in a Separase protein level-related manner, we silenced espl1 transcript levels in BV-173 and
LAMA-84 cells and monitored the influence of decreased transcript and protein levels on
Separase proteolytic activity (Fig 3). Treatment of BV-173 and LAMA-84 cells with espl1-selec-
tive siRNA for 48h revealed decreased espl1 transcript levels 53.8 (CI95%: -58.3 to -49.3) and
59.6 (CI95%: -66.2 to -52.9), respectively) and Separase protein levels 11.7 (CI95%: -15.1 to
38.5) and 18.5 (CI95%: -28.1 to 64.9), respectively). As a consequence, the Separase activity lev-
els rose in both b2a2 and b3a2 cell lines reaching levels of 118.5% (CI95%: 95.5 to 141.6)
(p = 0.0427) in BV-173 and 128.2 (CI95%: 85.4 to 171.1) (p = 0.0473) in LAMA-84 cells when
compared to mock transfected control cells. Obviously, less Separase protein molecules per-
formed more proteolytic activity resulting in an approximately 7-fold and 10-fold posttransla-
tional activation of residual Separase molecules in LAMA-84 and BV-173 cells, respectively.
This was mirrored by Securin and CyclinB1 protein levels (data not shown).
Discussion
Our data show an about 4-fold (ratio 6.3 vs. 1.6) preference for acquisition of unbalanced over
balanced ACA in IM-treated patients with the b3a2 fusion type when compared to patients
with the b2a2 fusion. New unbalanced ACA under therapy had a negative impact on prognosis
as they concurred with a higher incidence of BC in b3a2 patients (24% vs. 17%). These findings
complement our earlier observations which demonstrated a negative prognostic impact of un-
balanced ACA at diagnosis. [12] Moreover, it harmonises with previous data of the European
LeukemiaNet stating that newly arising ACA under imatinib treatment and clonal evolution
are considered features of acceleration and indicate failure of therapy. [3] This result points to
existence of a molecular mechanism exclusively in b3a2 fusion type cells that merges chromo-
somal missegregation with imatinib treatment and an inhibited p210BCR-ABL tyrosine kinase.
Several lines of evidence suggest also involvement of the centrosome:
i) Patel and Gordon reported that p210BCR-ABL and p145ABL are both centrosome-asso-
ciated proteins that interact with the pericentriolar protein pericentrin. Furthermore, when
CML cells were treated with imatinib there was a 55% and 20% reduction of p210BCR-ABL
and p145ABL binding to pericentrin, respectively. They also observed abnormally high levels
of Separase in CML CP and BC cells in comparison to normal CD34+ cells. [24] ii) We have
previously demonstrated that supernumerary centrosomes are an early detectable feature in
CML and contribute to chromosomal instability. In CML BC an increase in the percentage of
centrosome aberrant cells significantly correlated with aneuploid karyotypes. [17] The expres-
sion of p210BCR-ABL (TetOn system) is able to drive centrosomal amplification and clonal
evolution in a human in vitro CML model. [23] iii) Treatment of normal, p210BCR-ABL-
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negative and disease-unrelated cells with imatinib or other TKI induced centrosome aberra-
tions in vitro and in vivo. [26,29]
Based on these cumulative data, we set out to investigate the role of Separase as a major key
player in centrosomal duplication and chromosomal segregation during mitosis and to per-
form protein biochemical studies on Separase expression and activity profiles in human CML
cells.
However, the study of Separase in clinical samples from CML patients under TKI treatment
is associated with several problems. The major difficulty is the limited amount of bcr-abl-
positive tumor cells under IM treatment. Under IM treatment about 70% of patients show
fast response with bcr-abl transcript levels10% at 3 months,1% at 6 months and0.1%
(= MMR, major molecular response) from 12 months onward. Frequently, deeper molecular
responses with a bcr-abl log reduction on the international scale (IS) of 4 (MR4) or 4.5 (MR4.5)
are achieved. [49] Accessing routine blood samples it is impossible to isolate a sufficient num-
ber of bcr-abl-positive progenitor cells for experiments. Patients with AP and BC are very rare
and bone marrow samples are hardly available. Moreover, individual co-morbidities and/or
co-medications may influence the proliferation of target cells and hence weaken experimental
results.
To overcome these difficulties, we conceived a systematic study using traditional cell culture
systems representing a panel of thoroughly characterized CML cell lines. This approach offers
a much more homogenous genetic background than clinical samples and provides the appro-
priate controls to evaluate Separase in the absence of IM or after RNAi silencing. We investigat-
ed the influence of IM on Separase protein levels and Separase proteolytic activity in a panel of
Fig 3. Separase expression and proteolytic activity after espl1 silencing by RNAi. BV-173 (b2a2) and LAMA-84 (b3a2) cells were treated with negative
control siRNA (control) and espl1-specific siRNA (siRNA) for 48h. Consecutively, Separase expression was analysed on transcript level (qRT-PCR), protein
level (Western blot immunostaining) and proteolytic activity level (fluorometric assay). All protein analyses were performed as described in legend to Fig 1. In
qRT-PCR analysis the house-keeping gene gus (beta-glucuronidase) served as internal standard. Abbreviations: RFU, relative fluorescence units. As for
interpretation, 11.7% of Separase protein (middle panel, p<0.0001) performs 118.5% proteolytic activity in BV-173 cells (right panel, p = 0.0427)
corresponding to an about 10fold posttranslational activation of present Separase molecules (118.5%/11.7% = 10.1).
doi:10.1371/journal.pone.0129648.g003
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six well characterized human cell lines with focus on cells expressing the b3a2 (K562, LAMA-
84) and b2a2 (KCL-22, BV-173) fusion type of p210BCR-ABL. These experiments confirmed
and expanded our recently published data where solely b3a2 cell lines have been investigated.
[42]
We were able to confirm our recent data on K562 and LAMA-84 cell lines (b3a2) where IM
treatment led to considerable decreases in Separase protein levels and unexpected activation of
Separase proteolytic activity (Fig 2C). The approximately 5.4-fold and 2.5-fold (CI95%: 1.9 to
3.7) (Table 4) increase in Separase activity in LAMA-84 and K562 cells, respectively, confirms
that Separase proteolytic activity is controlled on posttranslational level and independent of
p210BCR-ABL tyrosine kinase activity. [42]
In contrast, in b2a2 fusion type cells (KCL-22, BV-173) and in non-malignant UROtsa cells
we found slightly decreased or unchanged Separase protein levels. This becomes apparent in
the calculated quotients of Separase activity [%]/Separase protein level [%] (Table 4). Quotients
ranging around 1.0 (UROtsa, 0.9; KCL-22, 1.2; BV-173, 1.1) point to a constant activity/protein
ratio. Slight alterations compared to corresponding untreated cells are probably due to the anti-
proliferative effects of IM in BCR-ABL-positive cells (KCL-22, BV-173) as IM treatment re-
sulted in slight decreases in the proportion of G2/M and S phase cells while the amount of
apoptotic cells was stable below 12% (data not shown). When we tried to mimic the observed
posttranslational upregulation of Separase proteolytic activity in b3a2 cells by RNAi-related
espl1 silencing (Fig 3) we observed a striking increase in Separase activation in both b3a2
(LAMA-84, 7-fold) and b2a2 (BV-173, 10-fold) cells.
Overall, our results point to the existence of two corresponding mechanisms contributing to
the observed Separase regulation in p210BCR-ABL positive cells. i) Selective downregulation of
Separase protein levels by IM treatment exclusively in b3a2 cells, but not in b2a2 cells. ii) Post-
translational hyperactivation of the remaining Separase molecules to functionally compensate
for the dropped Separase protein levels. This latter mechanism is p210BCR-ABL-dependent as
it was not observed in NHDF cells but it does not rely on the kinase activity of p210BCR-ABL
because hyperactivation occurred in face of IM treatment. Since hyperactivation of Separase
proteolytic activity can be induced also in b2a2 fusion type cells (BV-173) by siRNA-mediated
downregulation of Separase protein levels, the responsible actuator seems to be solely associat-
ed with the diverging response of b3a2 and b2a2 to IM treatment. Biochemically, it may be
traced back to the additional 25 amino acid residues within the b3a2 p210BCR-ABL
oncoprotein.
Studies from the pre-IM era have proposed that a sequential arrangement of six hydropho-
bic amino acid residues (F-L-N-V-I-V) encoded by bcr exon e14 (b3) may alter juxtaposition
of p210BCR-ABL domains and subsequently, may change the binding kinetics for interacting
protein partners. [50] Therefore, we speculate that differential protein interacting capabilities
of the b3a2 and b2a2 fusion proteins may alter either expression or stability of Separase in IM
treated CML cells. So far, the corresponding regulatory protein partners are unknown, but a
varying recruitment of p210BCR-ABL to the centrosome may conceivable. [24]
The observed hyperactivation of Separase in b3a2 cells correlates with our cytogenetic data
and points to higher “escape skills” of b3a2 leukemic stem cells that obviously outperform b2a2
cells in terms of unbalanced ACA acquisition and clonal evolution. The increased potential for
clonal evolution and development of resistance may help b3a2 progenitors to escape the immu-
nological and therapeutic pressure in terms of the Darwinian tumor model (“survival of the fit-
test”). [51] This assumption is concordant with the pathology of CML: Development of
resistance in patients undergoing IM therapy frequently concurs with clonal evolution, which
points to clonal evolution as a mechanism of resistance. [52,53] Furthermore, under IM the
outcome of patients with clonal evolution is significantly inferior compared to those without.
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[6] It is therefore tempting to speculate that the IM-related hyperactivation of Separase proteo-
lytic activity exclusively in b3a2 bcr-abl-positive cells is the best candidate mechanism for ex-
plaining promotion of tumor heterogeneity and clonal evolution. Even in dormant
p210BCR-ABL low-expressing quiescent stem cells, this mechanism may eventually create de-
scendant cell populations with enhanced fidelity to escape therapeutic pressure. [4,7] This suits
the general opinion that newly arising ACA under treatment are a clear sign of therapy failure.
[3,12] Our data seem to contradict the general opinion that b3a2 patients show better molecu-
lar responses than b2a2 patients. However, no difference in cytogenetic response and overall
survival has been previously reported when comparing the impact of b3a2 and b2a2 splice vari-
ants on disease phenotype and outcome under imatinib therapy. [54] Therefore, we conclude
that our proposed Separase-related mechanism favoring specifically the acquisition of unbal-
anced ACA in b3a2 patients has no detectable influence on clinical response and overall surviv-
al. However, our clinical results clearly demonstrate that there are differences between b2a2
and b3a2 patients during IM treatment in terms of ACA type (unbalanced preferred) and time
to blast crisis. These differences seem to be clinically relevant. Because of the rather small sam-
ple size and the relatively low number of statistical tests performed (4) we refrained from Bon-
ferroni correction in order to control the overall type I error rate. Otherwise, differences
between both groups may have been missed. However, even if the p value is multiplicated by 4
(according to Bonferroni correction) the difference regarding “time to BC” remains statistically
significant (p = 0.0496) whereas the difference regarding the p210BCR-ABL splice variant
shows a trend (p = 0.0984).
In conclusion, our data indicate the existence of a p210BCR-ABL-related feedback mecha-
nism that posttranslationally stimulates Separase proteolytic activity after an IM-induced de-
crease in Separase protein levels exclusively in b3a2 fusion type CML cells. As a consequence,
b3a2 cells may be more susceptible to chromosomal missegregation (aneuploidy) and clonal
evolution than leukemic b2a2 progenitors. Prospective studies on the Separase regulatory net-
work in CML may give rise to new concepts in carcinogenesis and leukemia therapy using se-
lective Separase inhibitors. [55]
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